Clinical-stage biopharmaceutical company discovering and developing novel biologic medicines for hard-to-treat cancers and Alzheimer’s disease
Clinical-stage biopharmaceutical company discovering and developing novel biologic medicines for hard-to-treat cancers and Alzheimer’s disease. Its pipeline includes immuno-oncology antibodies targeting CTLA-4, PD-1/VEGF, CD24, and Siglec pathways, as well as programs aimed at neurodegenerative disease.